About Helix Biopharma (TSE:HBP)
Helix BioPharma Corp. is an immuno-oncology company, which specializes in the field of cancer therapy. The Company is developing products for the prevention and treatment of cancer based on its technologies. The Company's product development initiatives are focused primarily on technologies that modulate the tumor microenvironment. The Company's technology platform, DOS47 yielded approximately two drug product candidates, L-DOS47 and vDOS47. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. L-DOS47 is under clinical study for the treatment of non-small cell lung cancer (NSCLC). L-DOS47 has completed preclinical testing and manufacturing development, following which, regulatory approvals are obtained in Poland and the United States to conduct Phase I/II and Phase I clinical studies. V-DOS47 is an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2).
Industry, Sector and Symbol
Trailing P/E Ratio-9.4
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-874.75%
Return on Assets-294.09%
Helix Biopharma (TSE:HBP) Frequently Asked Questions
What is Helix Biopharma's stock symbol?
Helix Biopharma trades on the Toronto Stock Exchange (TSX) under the ticker symbol "HBP."
How were Helix Biopharma's earnings last quarter?
Helix Biopharma Corp. (TSE:HBP) issued its earnings results on Wednesday, December, 13th. The biopharmaceutical company reported ($0.02) EPS for the quarter. View Helix Biopharma's Earnings History.
When will Helix Biopharma make its next earnings announcement?
Who are some of Helix Biopharma's key competitors?
Some companies that are related to Helix Biopharma include Medgenics (GNMX), ContraFect (CFRX), Anavex Life Sciences (AVXL), Trillium Therapeutics (TRIL), Concordia International (CXR), Soligenix (SNGX), Windtree Therapeutics (WINT), Mateon Therapeutics (MATN), Affymax (AFFY), Tetralogic Pharmaceuticals (TLOG), Cubist Pharmaceuticals (CBST), Idenix Pharmaceuticals (IDIX) and Onyx Pharmaceuticals (ONXX).
Who are Helix Biopharma's key executives?
Helix Biopharma's management team includes the folowing people:
- Sven Rohmann M.D., Ph.D., Chairman of the Board (Age 52)
- Heman Chao Ph.D., Chief Executive Officer, Chief Scientific Officer (Age 54)
- Photios Michalargias, Chief Financial Officer (Age 50)
- George J. Anders, Director
- Sylwester Eugeniusz Cacek, Director
- Theordore Witek Jr., Director
- Slawomir Majewski M.D., Independent Director (Age 57)
- Marek Jan Orlowski, Independent Director (Age 47)
How do I buy Helix Biopharma stock?
Shares of Helix Biopharma and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Helix Biopharma's stock price today?
One share of Helix Biopharma stock can currently be purchased for approximately C$0.94.
How big of a company is Helix Biopharma?
Helix Biopharma has a market capitalization of C$95.65 million.
How can I contact Helix Biopharma?
Helix Biopharma's mailing address is 21 St Clair Ave E Suite 1100, TORONTO, ON M4T 1L9, Canada. The biopharmaceutical company can be reached via phone at +1-416-9253232.
MarketBeat Community Rating for Helix Biopharma (HBP)MarketBeat's community ratings are surveys of what our community members think about Helix Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Helix Biopharma (TSE:HBP) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Helix Biopharma (TSE:HBP) Earnings History and Estimates Chart
Helix Biopharma (TSE HBP) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/16/2018|| || || || || || || || |
|12/13/2016||Q1 2017||C($0.04)||C$0.03 million||View||N/A|
Helix Biopharma (TSE:HBP) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Helix Biopharma (TSE:HBP)
No dividend announcements for this company have been tracked by MarketBeat.com
Helix Biopharma (TSE HBP) Insider Trading and Institutional Ownership History
Helix Biopharma (TSE HBP) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|7/26/2017||Marek Jan Orlowski||Director||Sell||5,000||C$0.90||C$4,500.00|
Helix Biopharma (TSE HBP) News Headlines
Helix Biopharma (TSE:HBP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Helix Biopharma (TSE HBP) Stock Chart for Thursday, February, 22, 2018